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mTOR Is Activated in the Majority of Malignant
Melanomas
Magdalena Karbowniczek1, Cynthia S. Spittle2, Tasha Morrison1, Hong Wu3 and Elizabeth P. Henske1
The objective of this study was to determine whether activation of the kinase mammalian target of rapamycin
(mTOR) is associated with human melanoma. We found moderate or strong hyperphosphorylation of ribosomal
protein S6 in 78/107 melanomas (73%). In contrast, only 3/67 benign nevi (4%) were moderately positive, and
none were strongly positive. These data indicate that mTOR activation is very strongly associated with
malignant, compared to benign, melanocytic lesions. Next, we tested six melanoma-derived cell lines for
evidence of mTOR dysregulation. Five of the six lines showed persistent phosphorylation of S6 after 18 hours of
serum deprivation, and four had S6 phosphorylation after 30minutes of amino-acid withdrawal, indicating
inappropriate mTOR activation. The proliferation of three melanoma-derived lines was blocked by the mTOR
inhibitor rapamycin, indicating that mTOR activation is a growth-promoting factor in melanoma-derived cells.
mTOR is directly activated by the small guanosine triphosphatase Ras homolog enriched in brain (Rheb), in a
farnesylation-dependent manner. Therefore, to investigate the mechanism of mTOR activation, we used the
farnesyl transferase inhibitor FTI-277, which partially blocked the growth of three of the six melanoma cell lines.
Together, these data implicate activation of mTOR in the pathogenesis of melanoma, and suggest that Rheb and
mTOR may be targets for melanoma therapy.
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INTRODUCTION
In the United States in the past 40 years, the incidence of
melanoma has increased 15-fold, more than any other malig-
nancy (Chudnovsky et al., 2005). Currently, 62,190 melano-
mas are diagnosed each year in the United States, with 7,900
deaths (Cancer Facts Figures ACS, 2006). There have been
many advances in melanoma pathogenesis (Rodolfo et al.,
2004; Chudnovsky et al., 2005; Thompson et al., 2005),
including the identification of activating B-Raf mutations in the
majority of tumors (Davies et al., 2002; Gray-Schopfer et al.,
2005). However, no current treatment is known to enhance
the survival of patients with advanced disease (Tsao et al.,
2004; Chudnovsky et al., 2005; Thompson et al., 2005).
Therefore, to develop optimal targeted therapeutic agents,
continuing to identify the cellular pathways that promote the
growth and progression of melanoma remains a priority.
The mammalian target of rapamycin (mTOR) is a kinase
that integrates growth factor stimulation and nutrient availa-
bility with protein synthesis and cell growth (Thomas and
Hall, 1997; Hara et al., 1998; Avruch et al., 2001; Sabatini,
2006). Activation of mTOR leads to phosphorylation and
activation of p70 ribosomal S6 kinase and eukaryotic
initiation factor 4E-binding protein 1, thereby promoting
increased protein translation and cell growth. Rapamycin has
been previously found to inhibit the growth of three
melanoma-derived cell lines and to inhibit the phosphory-
lation of ribosomal protein S6 in a melanoma-derived cell
line (Molhoek et al., 2005).
mTOR is activated by the small guanosine triphosphatase
Ras homolog enriched in brain (Rheb) (Castro et al., 2003;
Garami et al., 2003; Inoki et al., 2003; Saucedo et al., 2003;
Stocker et al., 2003; Tee et al., 2003; Zhang et al., 2003),
which is the target of the guanosine triphosphatase-activating
domain of the tuberous sclerosis complex 2 (TSC2) protein. In
addition to Rheb’s activation of mTOR, Rheb also inhibits the
activity of B-Raf and C-Raf kinase (Karbowniczek et al., 2004,
2006).
Because Rheb activity is regulated by the TSC2 protein,
Rheb and mTOR are activated in tumor cells from patients
with TSC. TSC is a tumor-suppressor gene disorder charac-
terized by seizures, mental retardation, and benign tumors in
multiple organs. The abnormal smooth muscle cells of renal
angiomyolipomas and pulmonary lymphangioleiomyo-
matosis, two of the characteristic lesions of TSC, have been
known for many years to express melanocytic antigens, inclu-
ding HMB-45, melan-A, CD63, and PNL2 (Chan et al., 1993;
Makhlouf et al., 2002; Tuna et al., 2003; Zhe and Schuger,
2004). This expression of melanoma-associated antigens in
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TSC tumors, together with the role of TSC2 and Rheb in
regulating the activity of B-Raf kinase (Karbowniczek et al.,
2004, 2006), led us to ask whether the mTOR pathway is
activated in human melanoma. In this study, we investigated
the presence of hyperphosphorylation of ribosomal protein
S6, a marker of mTOR activation, in human melanocytic
lesions and melanoma-derived cell lines, and the impact of
the mTOR inhibitor rapamycin and the farnesyl transferase
inhibitor (FTI)-277 on the growth of melanoma-derived cell
lines.
RESULTS
Hyperphosphorylation of ribosomal protein S6 is associated
with melanoma
To determine whether malignant melanomas exhibit activa-
tion of mTOR signaling in vivo, phospho-ribosomal protein
S6 immunostaining was performed on tissue microarrays
(TMAs) containing a total of 107 melanomas and 67 benign
nevi. The phosphorylation of ribosomal protein S6 is widely
used as an indicator of mTOR activity in human tumor
specimens (El-Hashemite et al., 2003; Karbowniczek et al.,
2003). Of the benign nevi, 43 (64%) were negative for
phospho-S6 staining, 21 (31%) were weakly (1þ ) positive,
and only 3 (4%) were moderately (2þ ) positive (Figure 1a
and Table 1). None of the benign lesions showed strong
(3þ ) phospho-S6 positivity. In striking contrast to the
nevi, 78 (73%) of the melanomas were moderately or
strongly positive: 10/13 in situ melanomas, 18/27 invasive
melanomas, and 50/67 metastatic melanomas (Figure 1e and
Table 1). Identical staining intensities were observed for the
38 tumors present in duplicate on the arrays. Staining for total
S6 ribosomal protein showed similar amounts in benign nevi
and melanomas (data not shown). These findings suggest
that the mTOR signaling pathway is activated in the majority
of melanomas in vivo.
We obtained ‘‘full sections’’ and compared anti-phospho-
S6 immunostaining between the full sections and the TMA.
The first tumor had 2þ positivity in approximately 30–40% of
the melanoma cells on the TMA; in the full section, there was
2 to 3þ positivity in 50–60% of the cells. The second tumor
had 2þ positivity in 5–10% of the cells in the TMA; 1 to 2þ
positivity was present in 5% of the cells on the full section.
The third tumor had 3þ positivity in 50% of the cells on the
TMA; 2þ positivity was present in 30% of the cells on the full
section. Thus, there was a 5–20% variation in the proportion
of positive cells between the TMA and the full sections.
To determine whether mTOR activation is specific to
tumors carrying B-Raf or N-Ras mutations, we tested a series
of melanomas on the array for mutations within exon 15 of B-
Raf or N-Ras, using pyrosequencing on DNA prepared from
the archival paraffin-embedded sections. Sequencing was
successful for both genes in 35 tumors (including 23 with
moderate or strong hyperphosphorylation of ribosomal
protein S6; Table 2). Two additional tumors with a B-Raf
mutation (V600E) are included in Table 2 even though the
N-Ras sequencing was not successful. B-Raf or Ras mutations
were present in 25 of the 37 tumors (67.6%). Nineteen
mutations were found in B-Raf (15 V600E, 1 V600K, 1 L597R,
1 V600R, and 1 K601E). Six mutations were found in N-Ras
(15.8%), all of which were Q61K. No tumors had mutations
in both genes. Of the moderate and strong phospho-S6
tumors, 10 had B-Raf mutations and 4 had N-Ras mutations
(Table 2), suggesting that mTOR activation is independent
of B-Raf or N-Ras mutational status.
The mTOR pathway is activated in melanoma-derived cell lines
We next asked whether inappropriate activation of the
mTOR pathway is present in melanoma-derived cell lines.
We tested six cell lines, SK-MEL-2, SK-MEL-5, SK-MEL-28,
UACC-62, UACC-257, and M-14, and included mouse-
derived IMCD3 cells as a control. Five of the melanoma-
derived cell lines (SK-MEL-2, SK-MEL-5, SK-MEL-28, UACC-62,
and M-14) showed only a minor increase in phospho-S6
after serum stimulation (Figure 2, lane 2 vs 3), suggesting
dysregulation of the mTOR pathway. Rapamycin, which is a
specific inhibitor of the mTOR/Raptor complex (Brown et al.,
1994; Sabatini et al., 1994; Schmelzle and Hall, 2000; Kim
and Sabatini, 2004), inhibited the phosphorylation of S6 in all
cell lines, indicating that regulation of S6 in these cells is
mTOR complex 1-dependent.
Rapamycin inhibits the proliferation of melanoma-derived cell
lines
To determine whether inappropriate activation of mTOR
promotes the growth of melanoma-derived cell lines, we
tested the effect of mTOR inhibition on proliferation. In these
experiments, we focused on three cell lines with previously
identified melanoma-associated mutations: SK-MEL-28 and
Malme (both of which carry the V600E B-Raf mutation) and
SK-MEL-2 (which has a Q61K N-Ras mutation). The cells
were treated with 20 nM rapamycin or DMSO vehicle control
for 3 days, and the incorporation of 3H-thymidine was mea-
sured daily. Rapamycin strongly inhibited the growth of all
three melanoma-derived cell lines. Both of the V600E B-Raf
mutant lines showed a statistically significant difference in
thymidine incorporation after 24 hours of rapamycin, where-
as the N-Ras mutant line (SK-MEL-2) reached significance
after 48 hours (Figure 3).
FTI-277 inhibits the proliferation of melanoma-derived cells
We treated six cell lines with 10 mM of the farnesylation-
transferase inhibitor FTI-277 for 3 days. FTI-277 significantly
inhibited the growth of three of the cell lines at the 3-day time
point: SK-MEL-2 by 70%, UACC-62 by 50%, and UACC-257
by 40% (Figure 4a). The small guanosine triphosphatase Rheb
directly activates mTOR, and Rheb is farnesylated (Clark
et al., 1997; Castro et al., 2003; Li et al., 2004; Basso et al.,
2005; Gau et al., 2005). Whether farnesylation of Rheb is
required for mTOR activation is not yet completely under-
stood. Farnesylation inhibitors have been shown to inhibit the
phosphorylation of S6 in MCF-7 cells (Basso et al., 2005)
and in Tsc1- and Tsc2-null mouse embryonic fibroblasts
(Gau et al., 2005), although a farnesyl-deficient form of
Rheb can also partially activate mTOR (Li et al., 2004).
Using lysates from cells treated in parallel with those used in
the proliferation assays, we found that phospho-S6 was
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significantly inhibited by FTI-277 in only SK-MEL-5 (Figure
4B). Therefore, these data suggest that the effects of the FTI
on growth of melanoma cells are primarily independent of
Rheb farnesylation.
DISCUSSION
Novel therapeutic strategies are urgently needed for patients
with advanced melanoma. Identifying the molecular path-
ways that promote the progression and metastasis of
melanoma is a key step toward this goal. We report here a
strong association between the phosphorylation of ribosomal
protein S6, an indicator of mTOR activation, and malignant
melanoma. Seventy-three percent of melanomas stained
moderately or strongly positive for phosphorylation of ribo-
somal protein S6, compared with only 4% of benign nevi.
These data indicate that mTOR activation occurs during the
pathogenesis of the majority of melanomas. To our knowl-
edge, hyperphosphorylation of ribosomal protein S6 is more
strongly associated with malignant versus benign melano-
cytic lesions than any other single marker. For example,
phosphorylation of Akt, which is strongly associated with
melanoma, has been reported in 71% of primary melanomas
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Figure 1. Phosphorylation of ribosomal protein S6 in dermal nevi and malignant melanoma. (a–d) Hematoxylin and eosin (left panels) and phospho-ribosomal
protein S6 (right panels) staining of a representative dermal nevus (a and b) and lentigo maligna melanoma (c and d). Weak phospho-S6 (1þ ) staining is
present in the dermal nevus (b, arrow), which contrasts with strong (3þ ) staining in the epidermis (b and d, open arrow). Strong (3þ ) phospho-S6
staining is evident in the lentigo maligna melanoma (d, arrow). (e–j) Hematoxylin and eosin and phospho-S6 staining of melanoma in situ (e and f), invasive
melanoma (g and h), and metastatic melanoma (i and j). Strong (3þ ) cytoplasmic phospho-S6 staining is evident in melanoma cells (f, h, and j arrows).
Bar¼20 mm (a–j). Bar¼ 50 mm (insets).
Table 1. Phospho-S6 results in benign nevi and malignant melanoma
Number of cases pS6 negative ()% (n) pS6 positive (1+)% (n) pS6 positive (2+)% (n) pS6 positive (3+)% (n)
Dermal nevi 67 64.2 (43) 31.3 (21) 4.5 (3) 0
Melanoma in situ 13 7.7 (1) 15.3 (2) 46 (6) 31 (4)
Invasive melanoma 27 7.4 (2) 26 (7) 22.2 (6) 44.4 (12)
Metastatic melanoma 67 4.5 (3) 21 (14) 25.3 (17) 49.2 (33)
Table 2. Mutational analysis in malignant melanoma
B-Raf N-Ras
pS6 staining n % wild type % mutant n % wild type % Q61K
— 2 50 50 2 50 50
1+ 10 20 801 10 90 10
2+ 3 66.6 33.42 2 50 50
3+ 22 59 413 21 85.7 14.3
1Seven mutations were V600E and one was V600R.
2K601E.
3Seven mutations were V600E, one was V600K, and one was L597R.
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but also in 20–54% of benign nevi (Dhawan et al., 2002;
Slipicevic et al., 2005). It is interesting to speculate that Akt
activation may be directly responsible for mTOR activation in
some melanomas, since Akt phosphorylates and inactivates
TSC2 (Potter et al., 2002; Manning et al., 2002) resulting in
activation of Rheb and mTOR. However, since Akt is also
phosphorylated in 20–54% of benign nevi, which lack mTOR
activation in our study, other stimuli in addition to Akt must
be required for mTOR activation.
To investigate further the role of mTOR activation in
melanoma pathogenesis, we examined six melanoma-
derived cell lines. Five of the lines showed evidence of
inappropriate mTOR activation after overnight serum depri-
vation, and four of them had persistent S6 phosphorylation
after an additional 30minutes of amino-acid deprivation.
Three cell lines were treated with the mTOR inhibitor
rapamycin, which completely blocked their growth. This
growth inhibition is consistent with previous work by
Molhoek et al. (2005), who showed that rapamycin inhibited
the growth of three other melanoma patient-derived cell lines
(VMN5A, VMN18, and VMN39). We next tested all six lines
for growth inhibition by the farnesylation inhibitor FTI-277.
Three of the lines were partially inhibited by FTI-277, but the
phosphorylation of S6 was not inhibited, suggesting that the
growth effects of FTI-277 are not mediated by the Rheb–
mTOR pathway. The absence of a strong effect of FTI on
the phosphorylation of S6 appears to be consistent with
the literature, in which strong effects of FTI on mTOR
activity have been observed almost exclusively in cells with
Rheb overexpression or TSC1/TSC2 deletion (Clark et al.,
1997; Castro et al., 2003; Li et al., 2004; Basso et al., 2005;
Gau et al., 2005) and rarely in cells with endogenous
expression levels of TSC1, TSC2, and Rheb.
We hypothesize that activation of Rheb and mTOR is a
common mechanism through which mutations and/or con-
stitutive activation of upstream genes and proteins contribute
to melanoma progression. If this hypothesis is correct, then
therapy targeted at Rheb or mTOR could benefit patients with
a variety of upstream lesions. For example, mutations in
phosphatase and tensin homolog deleted on chromosome
ten, which occur in approximately 10% of melanomas (Gray-
Schopfer et al., 2005), would be predicted to activate Akt,
which is known to inactive TSC2 (Inoki et al., 2002; Manning
et al., 2002; Potter et al., 2002), resulting in activation of
Rheb and mTOR. Similarly, Ras-induced activation of
phosphatidylinositol 30-kinase/Akt (Okano et al., 2000) and
ribosomal S6 kinase would be predicted to inactivate TSC2
(Roux et al., 2004), resulting in activation of Rheb and mTOR.
Interestingly, B-Raf activation should also theoretically
result in mTOR activation, because p42 mitogen-activated
protein kinase, which is a downstream effector of B-Raf,
directly phosphorylates and inactivates TSC2 (Ma et al.,
2005). However, we found that mTOR activation was
uncommon in benign nevi, despite the fact that the majority
of benign nevi carry activating B-Raf mutations. It is possible
that B-Raf activation, although not sufficient to activate
mTOR, synergizes with subsequent cellular events during
melanoma progression, resulting in the high level of mTOR
activation in malignant lesions. Further studies will be
needed to test this model.
In conclusion, we found that activation of mTOR is
strongly associated with malignant melanocytic lesions
in vivo, that the majority of melanoma-derived cell lines
display inappropriate mTOR activation in serum-deprivation
conditions, and that inhibition of mTOR blocks the prolifera-
tion of melanoma-derived cell lines. These data suggest
that mTOR inhibition may have clinical benefit in patients
with advanced melanoma, either alone or in combina-
tion with another targeted agent. Since mTOR activation is
strongly associated with malignant versus benign melanocyte
lesions, mTOR inhibition could also prove beneficial in the
adjuvant setting for patients with high-risk, mTOR-positive
tumors. Taken together, our data strongly support further
investigation of mTOR and Rheb as targets for therapy of
advanced melanoma.
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Figure 2. mTOR activation in melanoma-derived cell lines. Whole-cell
lysates from six melanoma-derived cell lines and mouse IMCD3 cells
(as a control for the antibody specificity) were immunoblotted with a
phospho-specific antibody to Ser 235/236 of ribosomal protein S6, in
conditions of steady-state growth in full serum, 24 hours serum deprivation,
24 hours serum deprivation followed by 10minutes stimulation with 20%
fetal bovine serum, 24 hours serum deprivation followed by 30minutes
amino-acid withdrawal, or 24 hours rapamycin in full serum. Of the six
melanoma lines, only UACC-257 showed the expected increase of phospho-
S6 after serum stimulation (compare second and third lanes). In all cell lines,
phospho-S6 was strongly inhibited by rapamycin (fifth lane). The mouse
IMCD3 cells show an increase of phospho-S6 after serum stimulation and
a decrease after amino-acid withdrawal and rapamycin treatment.
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MATERIALS AND METHODS
Tissue microarrays and immunohistochemistry
Tissue microarrays were generated by the Fox Chase Cancer Center
Tumor Bank Facility, with the approval of the Institutional Review
Board. A total of 67 benign nevi, 13 melanomas in situ, 27 invasive
melanomas, and 67 metastatic melanomas were included, with 38
lesions present in duplicate as an internal control. Four-micrometer
sections were deparaffinized in xylene and rehydrated in a gradient
series of ethanol. For antigen retrieval, sections were boiled in citric
buffer (10mM sodium citrate-trisodium salt dehydrate; Sigma, St Louis,
MO), pH 6.0, for 10minutes. Endogenous peroxidase activity was
blocked with 3% hydrogen peroxide in methanol for 15minutes at
room temperature. The sections were then incubated in a humidified
chamber with a rabbit polyclonal anti-phospho-S6 antibody (Ser235/
236; Cell Signaling Technology, Beverly, MA) overnight at 41C or with
goat IgG, as a negative control (Santa Cruz Technology, Santa Cruz,
CA). The slides were then washed, incubated with an enhanced,
human-absorbed, biotinylated affinity-purified goat secondary anti-
body from the Histostain-Plus Kit (Zymed, San Francisco, CA) for
10minutes at room temperature, then washed and incubated with
enhanced horseradish peroxidase-conjugated streptavidin (Zymed) for
10minutes at room temperature. After washing, the slides were
developed using AEC Chromogen Solution (Zymed) and lightly
counterstained with hematoxylin (Biomeda, Foster City, CA). Staining
intensity was scored semiquantitatively as negative (no staining), 1þ
(weakly positive), 2þ (moderately positive), or 3þ (strongly positive).
Cells and immunoblots
Melanoma cell lines were maintained in RPMI (Invitrogen, Carlsbad,
CA). IMCD3 cell line, used a control cell line, was maintained in
DMEM (Invitrogen). Where indicated, cells were serum-deprived for
24hours and/or treated for 24hours with 20nM rapamycin (Biomol
Research Laboratories, Plymouth Meeting, PA) or with 10mM FTI-277
(Calbiochem, La Jolla, CA). Cells were rinsed once in ice-cold 1
phosphate-buffered saline and then lysed in PTY buffer (50mM HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5, 50mM
NaCl, 5mM EDTA, 50mM NaF, 10mM Na4P2O7, and 1% Triton X-100)
supplemented with phosphatase inhibitor cocktail I and II (Sigma). Cell
lysates were resolved by SDS-PAGE and transferred onto Immobilon P
membranes (Millipore, Bedford, MA). The following antibodies
were used: anti-phospho-S235/236 S6 ribosomal protein and anti-S6
ribosomal protein (Cell Signaling Technology), and anti-b-actin (Sigma).
Mutational analysis
DNA was isolated from formalin-fixed, paraffin-embedded tissue
sections using the PicoPureTM DNA Extraction Kit (Arcturus,
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Figure 3. Rapamycin inhibits the proliferation of melanoma-derived cell lines. Treatment of the SK-MEL-2, SK-MEL-28, and Malme melanoma cell lines with
20 nM rapamycin (dashed lines) inhibited growth, compared with DMSO vehicle control (solid lines). *Po0.05 (Student’s t-test).
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Mountain View, CA) according to the manufacturer’s instructions.
A 228 bp region of B-Raf exon 15 was amplified by seminested PCR.
The second round of amplification was performed with the reverse
primer 50-biotinylated to facilitate single-strand DNA template
isolation for the pyrosequencing reaction. Successful and specific
amplification was verified by agarose gel electrophoresis. Prepara-
tion of the single-stranded DNA template for pyrosequencing was
performed using streptavidin-coated Sepharose beads (Amersham
Pharmacia Biotech, Piscataway, NJ). The pyrosequencing primer for
B-Raf was designed to screen codons 600–602 within exon 15 (B-Raf
PYROSEQ: 50-TGATTTTGGTCTAGCTACAG). The pyrosequencing
primers for N-Ras were reported previously (Sivertsson et al., 2002).
The sequencing-by-synthesis reaction of the complementary strand
was performed on a PSQ 96MA instrument (Pyrosequencing AB,
Uppsala, Sweden). For selected tumors, the B-Raf PCR amplicon
generated for pyrosequencing was also directly sequenced on the
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Figure 4. FTI-277 inhibits the proliferation of melanoma-derived cell lines. (a) Treatment of the SK-MEL-2, UACC-62, and UACC-257 cell lines with
10mM FTI-277 (dashed lines) inhibited growth by 70, 50, and 40%, respectively, compared with DMSO vehicle control (solid lines). *Po0.05 (Student’s t-test).
(b) Cells treated and harvested in parallel with those in panel (a) were lysed and analyzed by immunoblot. FTI-277 (third lane in each panel) partially inhibited
the phosphorylation of ribosomal protein S6 in SK-MEL-5 but not in the other lines. In all cell lines, the phosphorylation of S6 was strongly inhibited by
rapamycin (fourth lane).
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ABI Prisms 3100 system (B-Raf PCR forward: 50-ATGCTTGCTCT
GATAGGAA, B-Raf PCR reverse: 50-GCATCTCAGGGCCAAA).
Proliferation assays
Melanoma cell lines were maintained in RPMI (Invitrogen, Foster
City, CA). When indicated, cells were serum-deprived for 24 hours,
amino acid deprived for 30minutes, or treated for 24 hours with
20 nM rapamycin (Biomol Research Laboratories) or 10 mM FTI-277
(Calbiochem). For thymidine incorporation assays, 5 103 mela-
noma cells were plated in triplicate in 24-well plates. Twenty-four
hours after plating, 20 nM rapamycin or 10 mM FTI or DMSO vehicle
control was added. After either 72 or 96 hours of growth at 371C in a
5% CO2 humidified atmosphere, cells were labeled for 6 hours with
1mCi of 3H-thymidine directly added to the media. Six hours later,
cells were washed with phosphate-buffered saline, fixed in 5%
trichloroacetic acid for 30minutes at 41C, and lysed in 0.5ml of
0.5N NaOH/0.5% SDS. 3H-thymidine incorporation was measured
by scintillation counting. Results are expressed as means7SD.
Significance was evaluated using the Student’s t-test.
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